Conference details are as follows:
Date: Tuesday, March 21, 2017
Time: 11:45 a.m. CET
Location: CCIB Convention Centre, Barcelona, Spain
About Symic Bio
Symic Bio is a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which will initially target the prevention of peripheral vein graft failure and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
Investor ContactsGitanjali Jain OgawaThe Trout Group(646) [email protected]
Media ContactsDavid Schull or Rich AllanRusso Partners, LLC(212) 845-4271(646) [email protected]
[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-the-11th-annual-bio-europe-spring-conference-300422263.html
SOURCE Symic Bio